Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
Revolution Medicines reported updated Phase 1/2 data for RASONQUE (daraxonrasib) combined with gemcitabine and nab-paclitaxel as a possible first-line treatment for metastatic pancreatic cancer, presented at the ENA Symposium in Barcelona.
From the press release
REDWOOD CITY, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced encouraging updated results from the Phase 1/2 RMC-GI-102 open-label study evaluating RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel (GnP) as a potential first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC). The data will be presented today during a late-breaking oral session at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
As published for republication. The full text is at GlobeNewswire.
Who is reporting it
- GlobeNewswirefirst at Nov 19, 2026, 6:05 PM ESTRead at GlobeNewswire (opens in a new tab)
- Investing.comfirst at Nov 19, 2026, 6:08 PM ESTRead at Investing.com (opens in a new tab)
Story so far
Reported by 2 sources
Revolution Medicines presented updated Phase 1/2 data for RASONQUE (daraxonrasib) combined with gemcitabine and nab-paclitaxel as a possible first-line treatment for metastatic pancreatic cancer at the ENA Symposium in Barcelona.
- Nov 19, 2026, 6:05 PM EST · GlobeNewswire · this storyConfirmedRevolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
- Nov 19, 2026, 6:08 PM EST · Investing.comDevelopingRevolution Medicines reports updated pancreatic cancer trial data
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.